These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26845135)

  • 21. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.
    Ammazzalorso A; De Filippis B; Giampietro L; Amoroso R
    ChemMedChem; 2013 Oct; 8(10):1609-16. PubMed ID: 23939910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of drug resistance in cancer chemotherapy.
    Luqmani YA
    Med Princ Pract; 2005; 14 Suppl 1():35-48. PubMed ID: 16103712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enantioselective synthesis of PPAR (peroxisome proliferator-activated receptors) agonists and antagonists.
    Goya P; Perez-Fernandez R; Gonzalez-Muniz R; Elguero J
    Curr Top Med Chem; 2014; 14(10):1283-93. PubMed ID: 24758429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes.
    Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
    Curr Pharm Des; 2013; 19(40):7126-40. PubMed ID: 23829373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural products to prevent drug resistance in cancer chemotherapy: a review.
    Yuan R; Hou Y; Sun W; Yu J; Liu X; Niu Y; Lu JJ; Chen X
    Ann N Y Acad Sci; 2017 Aug; 1401(1):19-27. PubMed ID: 28891091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?
    Szumilak M; Wiktorowska-Owczarek A; Stanczak A
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33946916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
    Tan FH; Putoczki TL; Stylli SS; Luwor RB
    Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
    Tan CK; Zhuang Y; Wahli W
    Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
    Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
    Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: Multi-target Drug Discovery - Part II.
    Chen JN
    Curr Top Med Chem; 2017 Nov; 17(28):3081-3083. PubMed ID: 29197319
    [No Abstract]   [Full Text] [Related]  

  • 32. Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer?
    Wolf DA
    Cancer Cell; 2014 Dec; 26(6):788-795. PubMed ID: 25490445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
    Menendez-Gutierrez MP; Roszer T; Ricote M
    Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Onus of Sphingolipid Enzymes in Cancer Drug Resistance.
    Morad SAF; Cabot MC
    Adv Cancer Res; 2018; 140():235-263. PubMed ID: 30060811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.
    Ammazzalorso A; Carrieri A; Verginelli F; Bruno I; Carbonara G; D'Angelo A; De Filippis B; Fantacuzzi M; Florio R; Fracchiolla G; Giampietro L; Giancristofaro A; Maccallini C; Cama A; Amoroso R
    Eur J Med Chem; 2016 May; 114():191-200. PubMed ID: 26974385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid metabolism: peroxisome proliferator-activated receptors.
    van Heyningen C
    Curr Opin Lipidol; 2007 Aug; 18(4):470-2. PubMed ID: 17620865
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemotherapeutic resistance: a nano-mechanical point of view.
    Nyongesa CO; Park S
    Biol Chem; 2018 Nov; 399(12):1433-1446. PubMed ID: 30067509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion.
    Lorendeau D; Dury L; Nasr R; Boumendjel A; Teodori E; Gutschow M; Falson P; Di Pietro A; Baubichon-Cortay H
    Curr Med Chem; 2017; 24(12):1186-1213. PubMed ID: 27855620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
    Hong F; Xu P; Zhai Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.